Alnylam Pharmaceuticals
ALNY
#452
Rank
HK$402.48 B
Marketcap
HK$3,047
Share price
-1.52%
Change (1 day)
60.59%
Change (1 year)
Alnylam Pharmaceuticals Inc. is a biopharmaceutical company focused on the R&D and commercialization of RNA interference (RNAi) therapeutics for genetically defined diseases.

EPS for Alnylam Pharmaceuticals (ALNY)

EPS in 2025 (TTM): HK$0.67

According to Alnylam Pharmaceuticals 's latest financial reports the company's current EPS (TTM) is HK$0.70. In 2023 the company made an earnings per share (EPS) of -HK$27.47 an increase over its 2022 EPS that were of -HK$72.29.

EPS history for Alnylam Pharmaceuticals from 2012 to 2025

Annual EPS

Year EPS Change
2025 (TTM)HK$0.67
2023-HK$27.47-62%
2022-HK$72.2929.03%
2021-HK$56.03-3.36%
2020-HK$57.97-8.48%
2019-HK$63.347.67%
2018-HK$58.8339.74%
2017-HK$42.1012.94%
2016-HK$37.2738.84%
2015-HK$26.85-32.88%
2014-HK$40.00259.44%
2013-HK$11.13-31.25%
2012-HK$16.19

EPS for similar companies or competitors

Company EPS EPS differencediff. Country
Arrowhead Pharmaceuticals
ARWR
-HK$9.73-1,488.89%๐Ÿ‡บ๐Ÿ‡ธ USA
Regeneron Pharmaceuticals
REGN
HK$338.03 48,166.67%๐Ÿ‡บ๐Ÿ‡ธ USA
Sarepta Therapeutics
SRPT
-HK$21.32-3,144.44%๐Ÿ‡บ๐Ÿ‡ธ USA
OPKO Health
OPK
-HK$1.87-366.67%๐Ÿ‡บ๐Ÿ‡ธ USA
Regulus Therapeutics
RGLS
-HK$5.68-911.11%๐Ÿ‡บ๐Ÿ‡ธ USA
Novartis
NVS
HK$57.27 8,077.78%๐Ÿ‡จ๐Ÿ‡ญ Switzerland
Sanofi
SNY
HK$28.84 4,017.43%๐Ÿ‡ซ๐Ÿ‡ท France
Teva Pharmaceutical Industries
TEVA
HK$4.90 600.00%๐Ÿ‡ฎ๐Ÿ‡ฑ Israel